Featured announcement
Qihan Biotech named among China’s 2026 Future Unicorn Top 100
Qihan was also named to Hangzhou’s quasi-unicorn list for the seventh consecutive year.
Read announcementNews archive
Each headline opens the same example article to preview the news detail layout.
7 results
- Regulatory
China’s NMPA clears QT-019C for clinical testing
The clearance supports a planned Phase I study of the investigational therapy in refractory systemic lupus erythematosus.
- Regulatory
Qihan completes a pre-IND meeting with the FDA for an in vivo CAR-T candidate
- Clinical development
Qihan completes Phase I enrollment for its allogeneic CAR-T study
The company reported that Phase IIa enrollment was underway at the time of the announcement.
- Company recognition
Qihan Biotech named among China’s 2026 Future Unicorn Top 100
Qihan was also named to Hangzhou’s quasi-unicorn list for the seventh consecutive year.
- Yiyao Guanlan
Yiyao Guanlan interviews Qihan on its next steps in cell and organ therapy
- Company news
Qihan completes pre-Series B financing
The company announced a financing round of more than US$16 million.
- BioWorld
BioWorld covers Qihan’s $67 million financing for cell and organ therapies
Scientific publications
Explore Qihan’s peer-reviewed research in genome engineering and cell therapy.
Browse publicationsMedia inquiries
Contact our communications team for interviews and press materials.
media@qihanbio.com